SUMMARY

With more than 900 abstracts focusing on multiple myeloma (MM), the 2017 annual meeting of the American Society of Hematology (ASH) shows once more the great interest of the myeloma community in identifying new potential targets and developing novel therapeutic strategies for this devastating disease.

(BELG J HEMATOL 2018;9(1):8–11)